Exosomes Archives | Page 26 of 27

Salivary EVs, Exosomes, and the Future of Non-Invasive Diagnostics

February 6, 2018 By Cade Hildreth, Founder & President 1 Comment

I had the honor of interviewing Paul D Slowey, PhD, CEO of Oasis Diagnostics® Corporation, a company specializing in non-invasive saliva based technology for rapid testing, sample collection, and molecular diagnostics. Dr. Slowey is also the Organizer of the North American Saliva Symposium (NASS).

In this interview, we discuss his unique background, the rise of extracellular vesicles (EVs) and exosomes as diagnostic tools, advantages of saliva over other bodily fluids, and current and future applications for saliva-derived EVs and exosomes. [Read more…]

Will Exosomes Go Exponential? Exosome Companies Are Multiplying Fast

January 20, 2018 By Cade Hildreth, Founder & President 1 Comment

With 25% of all exosome publications released in the past year and exosome companies flooding into the marketplace, we are witnessing an exosome explosion. Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. Specifically, they transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.

Exosomes are commonly found in blood, urine, and saliva, among other fluids. Exosomes are also present in other body fluids, such as synovial fluid, amniotic fluid, semen, vaginal fluid, breast milk, and more.

It has been long known that stem cells have the potential to exert therapeutic effects, but it has only been recently recognized that exosomes play an important role how stem cells exert their cellular functions. [Read more…]

Exosome Manufacturing: $2.18M Grant Awarded to VivaZome Therapeutics

January 13, 2018 By Cade Hildreth, Founder & President Leave a Comment

$2.18m grant awarded to VivaZome Therapeutics for Exosome Therapy; Grant awarded in collaboration with La Trobe University and SeerPharma

18 December 2017, Geelong – Melbourne, Australia: Australian biotech company VivaZome Therapeutics is pleased to announce that it has been awarded an Australian Government CRC-P grant of $2.18m in support of the project “Enabling Exosome Therapy: Developing an Advanced Manufacturing Process”, with the funds provided under the Advanced Manufacturing Scheme.

The Hon Craig Laundy MP (Assistant Minister for Industry, Innovation and Science) oversees the Cooperative Research Centre Projects (CRC-P) Grants Scheme which supports the development of innovative Australian companies and sectors.

Joining VivaZome in the CRC-P are La Trobe University and SeerPharma Pty Ltd, each of which bring high-level scientific and operational skills to the 3 –year project. VivaZome will also engage with the CSIRO to provide expertise in industrial–scale manufacturing. [Read more…]

ArunA Biomedical Launches Exosome Biologics to Treat CNS and Neurodegenerative Disorders

January 11, 2018 By Cade Hildreth, Founder & President Leave a Comment

Company rapidly moving toward clinical development of cell-free biologic therapy as study published in Translational Stroke Research demonstrates human neural exosomes improve tissue and functional recovery in pre-clinical model

January 03, 2018 08:00AM, ATHENS, Ga. — ArunA Biomedical announces the official launch of a new class of cell-free exosome biologics to treat central nervous system and neurodegenerative disorders. With an initial focus on an exosome therapeutic for stroke, the company published results of a study today in Translational Stroke Research that found extracellular vesicles (EVs) derived from human neural stem cells improved tissue and functional recovery in murine thromboembolic stroke models.

The study was led by Dr. Steven Stice, a Georgia Research Alliance Eminent Scholar endowed chair, Professor and Director of the Regenerative Bioscience Center at The University of Georgia and who serves as Co-Founder, Chief Executive and Chief Scientific Officer for ArunA Biomedical. The study was conducted in collaboration with Dr. Nasrul Hoda at Augusta University. [Read more…]

BioInformant Releases “Market for Stem Cell Exosomes”

December 27, 2017 By Cade Hildreth, Founder & President Leave a Comment

Washington DC (Newswire) — BioInformant has launched the “Market for Stem Cell Exosomes – Products, Services, & Technologies,” a global strategic report targeting the growing demand for exosome therapeutics, diagnostics, and research tools.

Exosomes are rapidly gaining momentum as a strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients. With exosome companies multiplying in number and exosome publications on the rise, it is clear that exosomes will play a crucial role in the cell therapy movement.

Based in Washington, DC, BioInformant is the first and only market research firm to specialize in the stem cell industry. With more than a decade of experience in tracking the stem cell industry (2006 to present), BioInformant has a robust database on which to base future market predictions. Written for companies developing exosome-related products and technologies, the report analyzes strategic opportunities for commercializing products involving exosomes derived from stem cells, as well as other cell sources. [Read more…]